| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | lipoprotein lipase activity | 5.81e-05 | 9 | 180 | 3 | GO:0004465 | |
| GeneOntologyMolecularFunction | triacylglycerol lipase activity | 8.18e-05 | 26 | 180 | 4 | GO:0004806 | |
| GeneOntologyMolecularFunction | X11-like protein binding | 2.41e-04 | 3 | 180 | 2 | GO:0042988 | |
| GeneOntologyMolecularFunction | granulocyte colony-stimulating factor receptor binding | 2.44e-04 | 14 | 180 | 3 | GO:0005130 | |
| GeneOntologyBiologicalProcess | homophilic cell adhesion via plasma membrane adhesion molecules | FAT4 CEACAM5 PSG4 CDHR2 PCDHGA11 CLSTN2 CLSTN1 CADM2 TENM3 PKD1 PSG8 | 7.49e-07 | 187 | 179 | 11 | GO:0007156 |
| GeneOntologyBiologicalProcess | regulation of homophilic cell adhesion | 1.53e-05 | 18 | 179 | 4 | GO:1903385 | |
| GeneOntologyBiologicalProcess | cell-cell adhesion via plasma-membrane adhesion molecules | FAT4 CEACAM5 PSG4 CDHR2 PCDHGA11 CLSTN2 CLSTN1 TENM2 CADM2 TENM3 PKD1 PSG8 | 1.96e-05 | 313 | 179 | 12 | GO:0098742 |
| GeneOntologyBiologicalProcess | regulation of cholesterol storage | 2.38e-05 | 20 | 179 | 4 | GO:0010885 | |
| GeneOntologyBiologicalProcess | cell growth | SEMA3F CEACAM5 DDX49 PSG4 CDHR2 RPS6KA3 SMURF1 SRF SPART SPG11 CLSTN1 ADAM10 MEX3C RPTOR MACF1 ROS1 PSG8 | 3.32e-05 | 625 | 179 | 17 | GO:0016049 |
| GeneOntologyBiologicalProcess | protein catabolic process | TPP2 STAM2 VPS11 CEACAM5 PSG4 FOLH1 RC3H1 UBR4 SMURF1 SPG11 APOB ADAM10 FOXRED2 FBXO10 GPC3 ASB5 GID4 SERPINB12 PKD1 LRP2 PSG8 ATM EIF2A FEM1A | 3.68e-05 | 1115 | 179 | 24 | GO:0030163 |
| GeneOntologyBiologicalProcess | regulation of cell growth | SEMA3F CEACAM5 DDX49 PSG4 CDHR2 RPS6KA3 SMURF1 SRF SPART CLSTN1 ADAM10 RPTOR MACF1 ROS1 PSG8 | 4.96e-05 | 519 | 179 | 15 | GO:0001558 |
| GeneOntologyBiologicalProcess | multi-pass transmembrane protein insertion into ER membrane | 5.20e-05 | 9 | 179 | 3 | GO:0160063 | |
| GeneOntologyBiologicalProcess | cholesterol storage | 7.06e-05 | 26 | 179 | 4 | GO:0010878 | |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 8.69e-05 | 52 | 179 | 5 | GO:0031342 | |
| GeneOntologyBiologicalProcess | lipid biosynthetic process | SMG1 ABCC1 CEACAM5 PSG4 CES1 UBR4 DGKQ APOB ACSS2 ACOX2 MTMR7 LIPG RPTOR PI4KA LPL FGF1 PSG8 ATM ABHD1 | 8.75e-05 | 813 | 179 | 19 | GO:0008610 |
| GeneOntologyBiologicalProcess | monocarboxylic acid biosynthetic process | 9.52e-05 | 260 | 179 | 10 | GO:0072330 | |
| GeneOntologyBiologicalProcess | regulation of cholesterol metabolic process | 9.53e-05 | 53 | 179 | 5 | GO:0090181 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte proliferation | 1.06e-04 | 124 | 179 | 7 | GO:0050672 | |
| GeneOntologyBiologicalProcess | negative regulation of mononuclear cell proliferation | 1.17e-04 | 126 | 179 | 7 | GO:0032945 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte proliferation | 1.71e-04 | 134 | 179 | 7 | GO:0070664 | |
| GeneOntologyBiologicalProcess | negative regulation of brown fat cell proliferation | 2.18e-04 | 14 | 179 | 3 | GO:0070348 | |
| GeneOntologyBiologicalProcess | fatty acid biosynthetic process | 2.71e-04 | 191 | 179 | 8 | GO:0006633 | |
| GeneOntologyBiologicalProcess | regulation of brown fat cell proliferation | 2.71e-04 | 15 | 179 | 3 | GO:0070347 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immune response to tumor cell | 2.71e-04 | 15 | 179 | 3 | GO:0002856 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 2.71e-04 | 15 | 179 | 3 | GO:0002859 | |
| GeneOntologyBiologicalProcess | positive regulation of homophilic cell adhesion | 2.71e-04 | 15 | 179 | 3 | GO:1903387 | |
| GeneOntologyBiologicalProcess | regulation of lipid biosynthetic process | 3.08e-04 | 246 | 179 | 9 | GO:0046890 | |
| GeneOntologyBiologicalProcess | regulation of hepatocyte proliferation | 3.22e-04 | 38 | 179 | 4 | GO:2000345 | |
| GeneOntologyBiologicalProcess | insulin receptor internalization | 3.31e-04 | 16 | 179 | 3 | GO:0038016 | |
| GeneOntologyBiologicalProcess | negative regulation of T cell proliferation | 3.44e-04 | 107 | 179 | 6 | GO:0042130 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid biosynthetic process | 3.56e-04 | 39 | 179 | 4 | GO:0045717 | |
| GeneOntologyBiologicalProcess | regulation of bone resorption | 3.57e-04 | 70 | 179 | 5 | GO:0045124 | |
| GeneOntologyBiologicalProcess | organelle assembly | DNHD1 STAM2 NSUN4 VPS11 STBD1 SYNE1 RC3H1 OBSCN SMURF1 SRF SPG11 AAAS NEGR1 TUBGCP3 ADAMTS16 ATM CFAP57 EIF2A CNOT1 HYDIN TCTN1 MYBPC2 | 3.63e-04 | 1138 | 179 | 22 | GO:0070925 |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 3.93e-04 | 40 | 179 | 4 | GO:0045953 | |
| GeneOntologyBiologicalProcess | brown fat cell proliferation | 4.00e-04 | 17 | 179 | 3 | GO:0070342 | |
| GeneOntologyBiologicalProcess | insulin catabolic process | 4.00e-04 | 17 | 179 | 3 | GO:1901143 | |
| GeneOntologyBiologicalProcess | granulocyte colony-stimulating factor signaling pathway | 4.00e-04 | 17 | 179 | 3 | GO:0038158 | |
| GeneOntologyBiologicalProcess | import into cell | NAT8L ABCC1 CEACAM5 BTBD8 PSG4 SYNE1 CKAP5 DGKQ SLC39A4 SPG11 ELMO1 MST1R MET COLEC12 GPC3 LRP10 MRC2 LRP11 LRP2 SLC39A6 PSG8 | 4.29e-04 | 1074 | 179 | 21 | GO:0098657 |
| GeneOntologyBiologicalProcess | lipid localization | ANO4 TTC39B ABCC1 CEACAM5 PSG4 CES1 SPG11 APOB TNFRSF11A LRP10 NEGR1 LIPG LPL PSG8 | 4.31e-04 | 565 | 179 | 14 | GO:0010876 |
| GeneOntologyBiologicalProcess | neutral lipid catabolic process | 4.32e-04 | 41 | 179 | 4 | GO:0046461 | |
| GeneOntologyBiologicalProcess | acylglycerol catabolic process | 4.32e-04 | 41 | 179 | 4 | GO:0046464 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 4.32e-04 | 41 | 179 | 4 | GO:0002716 | |
| GeneOntologyBiologicalProcess | circadian temperature homeostasis | 4.44e-04 | 4 | 179 | 2 | GO:0060086 | |
| GeneOntologyBiologicalProcess | acetate metabolic process | 4.44e-04 | 4 | 179 | 2 | GO:0006083 | |
| GeneOntologyBiologicalProcess | substrate localization to autophagosome | 4.44e-04 | 4 | 179 | 2 | GO:0061753 | |
| GeneOntologyBiologicalProcess | regulation of growth | SEMA3F CEACAM5 DDX49 PSG4 CDHR2 RPS6KA3 SMURF1 SRF ANKRD62 SPART CLSTN1 ADAM10 GPC3 RPTOR MACF1 ROS1 PSG8 | 4.47e-04 | 777 | 179 | 17 | GO:0040008 |
| GeneOntologyBiologicalProcess | enzyme-linked receptor protein signaling pathway | HJV DOCK3 COL4A2 DOK6 FAT4 CEACAM5 KALRN PSG4 SMURF1 ANKRD62 SPART DCN NOMO1 MST1R MET GPC3 LRP2 FGF1 ROS1 PSG8 LTBP3 NOMO3 | 6.33e-04 | 1186 | 179 | 22 | GO:0007167 |
| GeneOntologyBiologicalProcess | negative regulation of hepatocyte proliferation | 6.57e-04 | 20 | 179 | 3 | GO:2000346 | |
| GeneOntologyBiologicalProcess | regulation of bone remodeling | 6.61e-04 | 80 | 179 | 5 | GO:0046850 | |
| GeneOntologyBiologicalProcess | epithelial cell proliferation involved in liver morphogenesis | 6.73e-04 | 46 | 179 | 4 | GO:0072575 | |
| GeneOntologyBiologicalProcess | hepatocyte proliferation | 6.73e-04 | 46 | 179 | 4 | GO:0072574 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 7.31e-04 | 47 | 179 | 4 | GO:0001911 | |
| GeneOntologyBiologicalProcess | cholesterol homeostasis | 7.53e-04 | 124 | 179 | 6 | GO:0042632 | |
| GeneOntologyBiologicalProcess | negative regulation of activin receptor signaling pathway | 7.62e-04 | 21 | 179 | 3 | GO:0032926 | |
| GeneOntologyBiologicalProcess | negative regulation of fat cell proliferation | 7.62e-04 | 21 | 179 | 3 | GO:0070345 | |
| GeneOntologyBiologicalProcess | negative regulation of response to tumor cell | 7.62e-04 | 21 | 179 | 3 | GO:0002835 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response to tumor cell | 7.62e-04 | 21 | 179 | 3 | GO:0002838 | |
| GeneOntologyBiologicalProcess | behavior | CEACAM5 MAN2B1 KALRN PSG4 CKAP5 SRF ANKRD62 SPG11 CLSTN2 ACSS2 MET AAAS NEGR1 RPTOR MTNR1A MTNR1B LSAMP PSG8 | 7.71e-04 | 891 | 179 | 18 | GO:0007610 |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 7.82e-04 | 83 | 179 | 5 | GO:0002707 | |
| GeneOntologyBiologicalProcess | sterol homeostasis | 7.85e-04 | 125 | 179 | 6 | GO:0055092 | |
| GeneOntologyBiologicalProcess | liver morphogenesis | 8.57e-04 | 49 | 179 | 4 | GO:0072576 | |
| GeneOntologyBiologicalProcess | negative regulation of granulocyte differentiation | 8.77e-04 | 22 | 179 | 3 | GO:0030853 | |
| GeneOntologyBiologicalProcess | regulation of tissue remodeling | 8.89e-04 | 128 | 179 | 6 | GO:0034103 | |
| GeneOntologyBiologicalProcess | endocytosis | CEACAM5 BTBD8 PSG4 SYNE1 CKAP5 DGKQ SPG11 ELMO1 MST1R MET COLEC12 GPC3 LRP10 MRC2 LRP11 LRP2 PSG8 | 8.95e-04 | 827 | 179 | 17 | GO:0006897 |
| GeneOntologyBiologicalProcess | positive regulation of MAP kinase activity | 9.26e-04 | 129 | 179 | 6 | GO:0043406 | |
| GeneOntologyCellularComponent | cell surface | HJV CEACAM5 PSG4 FOLH1 PSG7 CLSTN2 TNFRSF11A CR1 CLSTN1 ADAM10 RTN2 FZD6 MST1R MET GPC3 LIPG MRC2 LPL PKD1 LRP2 SLC39A6 ROS1 PSG8 CCR8 ADGRA3 ENOX2 | 4.14e-06 | 1111 | 182 | 26 | GO:0009986 |
| GeneOntologyCellularComponent | multi-pass translocon complex | 5.25e-05 | 9 | 182 | 3 | GO:0160064 | |
| GeneOntologyCellularComponent | lateral plasma membrane | 1.36e-04 | 90 | 182 | 6 | GO:0016328 | |
| GeneOntologyCellularComponent | ER membrane insertion complex | 2.20e-04 | 14 | 182 | 3 | GO:0072379 | |
| GeneOntologyCellularComponent | transforming growth factor beta ligand-receptor complex | 3.34e-04 | 16 | 182 | 3 | GO:0070021 | |
| Domain | - | SEMA3F CEACAM5 STBD1 KALRN PSG4 PSG7 SPEG OBSCN IGDCC3 PKHD1L1 CADM2 NOMO1 MST1R MET NOMO2 NEGR1 NFKB2 LSAMP ROS1 PSG8 NOMO3 ADGRA3 MYBPC2 | 1.09e-07 | 663 | 180 | 23 | 2.60.40.10 |
| Domain | Ig-like_fold | SEMA3F CEACAM5 STBD1 KALRN PSG4 PSG7 SPEG OBSCN IGDCC3 PKHD1L1 CADM2 NOMO1 MST1R MET NOMO2 NEGR1 NFKB2 LSAMP ROS1 PSG8 NOMO3 ADGRA3 MYBPC2 | 3.32e-07 | 706 | 180 | 23 | IPR013783 |
| Domain | CarboxyPept-like_regulatory | 4.43e-07 | 17 | 180 | 5 | IPR008969 | |
| Domain | IGc2 | SEMA3F CEACAM5 KALRN PSG4 PSG7 SPEG OBSCN IGDCC3 CADM2 NEGR1 LSAMP PSG8 MYBPC2 | 4.77e-07 | 235 | 180 | 13 | SM00408 |
| Domain | Ig_sub2 | SEMA3F CEACAM5 KALRN PSG4 PSG7 SPEG OBSCN IGDCC3 CADM2 NEGR1 LSAMP PSG8 MYBPC2 | 4.77e-07 | 235 | 180 | 13 | IPR003598 |
| Domain | Carb-bd-like_fold | 5.67e-07 | 8 | 180 | 4 | IPR013784 | |
| Domain | PKD/Chitinase_dom | 1.01e-06 | 9 | 180 | 4 | IPR022409 | |
| Domain | PKD | 1.01e-06 | 9 | 180 | 4 | SM00089 | |
| Domain | PKD | 2.61e-06 | 11 | 180 | 4 | PS50093 | |
| Domain | PKD_dom | 2.61e-06 | 11 | 180 | 4 | IPR000601 | |
| Domain | - | 2.61e-06 | 11 | 180 | 4 | 2.60.40.670 | |
| Domain | DUF2012 | 3.50e-06 | 4 | 180 | 3 | PF09430 | |
| Domain | DUF2012 | 3.50e-06 | 4 | 180 | 3 | IPR019008 | |
| Domain | Ig_I-set | CEACAM5 KALRN SPEG OBSCN IGDCC3 CADM2 NEGR1 LSAMP ADGRA3 MYBPC2 | 1.60e-05 | 190 | 180 | 10 | IPR013098 |
| Domain | I-set | CEACAM5 KALRN SPEG OBSCN IGDCC3 CADM2 NEGR1 LSAMP ADGRA3 MYBPC2 | 1.60e-05 | 190 | 180 | 10 | PF07679 |
| Domain | - | SEMA3F VPS11 NBEAL1 STXBP5 ARPC1A DCAF12L2 MST1R MET AAAS RPTOR TLE6 CFAP57 EIF2A | 2.16e-05 | 333 | 180 | 13 | 2.130.10.10 |
| Domain | WD40/YVTN_repeat-like_dom | SEMA3F VPS11 NBEAL1 STXBP5 ARPC1A DCAF12L2 MST1R MET AAAS RPTOR TLE6 CFAP57 EIF2A | 2.30e-05 | 335 | 180 | 13 | IPR015943 |
| Domain | PKD | 2.99e-05 | 7 | 180 | 3 | PF00801 | |
| Domain | WD40_repeat_dom | VPS11 NBEAL1 STXBP5 ARPC1A UBR4 DCAF12L2 AAAS TENM3 RPTOR TLE6 CFAP57 EIF2A | 3.23e-05 | 297 | 180 | 12 | IPR017986 |
| Domain | IG | SEMA3F CEACAM5 KALRN PSG4 PSG7 SPEG OBSCN IGDCC3 CADM2 NEGR1 LSAMP PSG8 ADGRA3 MYBPC2 | 6.05e-05 | 421 | 180 | 14 | SM00409 |
| Domain | Ig_sub | SEMA3F CEACAM5 KALRN PSG4 PSG7 SPEG OBSCN IGDCC3 CADM2 NEGR1 LSAMP PSG8 ADGRA3 MYBPC2 | 6.05e-05 | 421 | 180 | 14 | IPR003599 |
| Domain | Lipo_Lipase | 9.24e-05 | 2 | 180 | 2 | IPR002330 | |
| Domain | Tyr_kinase_HGF/MSP_rcpt | 9.24e-05 | 2 | 180 | 2 | IPR016244 | |
| Domain | Mel_1A_rcpt | 9.24e-05 | 2 | 180 | 2 | IPR002278 | |
| Domain | ATM/Tel1 | 9.24e-05 | 2 | 180 | 2 | IPR015519 | |
| Domain | ig | 9.67e-05 | 190 | 180 | 9 | PF00047 | |
| Domain | Immunoglobulin | 9.67e-05 | 190 | 180 | 9 | IPR013151 | |
| Domain | ARM-type_fold | DOCK3 SMG1 VPS11 NBEAL1 UBR4 USP24 CKAP5 APOB ELMO1 RPTOR PI4KA ATM | 1.15e-04 | 339 | 180 | 12 | IPR016024 |
| Domain | IPT | 1.23e-04 | 27 | 180 | 4 | SM00429 | |
| Domain | CarboxyPept_regulatory_dom | 2.34e-04 | 13 | 180 | 3 | IPR014766 | |
| Domain | - | 2.34e-04 | 13 | 180 | 3 | 2.60.40.1120 | |
| Domain | IPT | 2.43e-04 | 32 | 180 | 4 | IPR002909 | |
| Domain | Rhs_assc_core | 2.75e-04 | 3 | 180 | 2 | IPR022385 | |
| Domain | Calsyntenin | 2.75e-04 | 3 | 180 | 2 | IPR026914 | |
| Domain | Melatonin_rcpt | 2.75e-04 | 3 | 180 | 2 | IPR000025 | |
| Domain | IG_LIKE | SEMA3F CEACAM5 KALRN PSG4 PSG7 SPEG OBSCN IGDCC3 CADM2 NEGR1 LSAMP PSG8 ADGRA3 MYBPC2 | 3.00e-04 | 491 | 180 | 14 | PS50835 |
| Domain | PI3/4_kinase_CS | 3.68e-04 | 15 | 180 | 3 | IPR018936 | |
| Domain | Ig-like_dom | SEMA3F CEACAM5 KALRN PSG4 PSG7 SPEG OBSCN IGDCC3 CADM2 NEGR1 LSAMP PSG8 ADGRA3 MYBPC2 | 3.82e-04 | 503 | 180 | 14 | IPR007110 |
| Domain | - | 4.49e-04 | 16 | 180 | 3 | 1.10.1070.11 | |
| Domain | PI3Kc | 4.49e-04 | 16 | 180 | 3 | SM00146 | |
| Domain | - | 5.27e-04 | 39 | 180 | 4 | 2.120.10.30 | |
| Domain | Tox-GHH_dom | 5.47e-04 | 4 | 180 | 2 | IPR028916 | |
| Domain | - | 5.47e-04 | 4 | 180 | 2 | 2.40.30.110 | |
| Domain | Tox-GHH | 5.47e-04 | 4 | 180 | 2 | PF15636 | |
| Domain | Ten_N | 5.47e-04 | 4 | 180 | 2 | IPR009471 | |
| Domain | Ten_N | 5.47e-04 | 4 | 180 | 2 | PF06484 | |
| Domain | GcvT/YgfZ_C | 5.47e-04 | 4 | 180 | 2 | IPR029043 | |
| Domain | TENEURIN_N | 5.47e-04 | 4 | 180 | 2 | PS51361 | |
| Domain | LH2 | 6.46e-04 | 18 | 180 | 3 | SM00308 | |
| Domain | PI3_PI4_kinase | 6.46e-04 | 18 | 180 | 3 | PF00454 | |
| Domain | PI3_4_KINASE_1 | 6.46e-04 | 18 | 180 | 3 | PS00915 | |
| Domain | PI3_4_KINASE_2 | 6.46e-04 | 18 | 180 | 3 | PS00916 | |
| Domain | PI3/4_kinase_cat_dom | 6.46e-04 | 18 | 180 | 3 | IPR000403 | |
| Domain | PI3_4_KINASE_3 | 6.46e-04 | 18 | 180 | 3 | PS50290 | |
| Domain | Kinase-like_dom | SMG1 KALRN SPEG RPS6KA3 OBSCN CDKL4 CHD9 MST1R MET PTPN13 PI4KA MACF1 ROS1 ATM | 7.96e-04 | 542 | 180 | 14 | IPR011009 |
| Domain | Glyco_hydro_38_C | 9.06e-04 | 5 | 180 | 2 | IPR011682 | |
| Domain | GCV_T | 9.06e-04 | 5 | 180 | 2 | PF01571 | |
| Domain | Alpha-mann_mid | 9.06e-04 | 5 | 180 | 2 | PF09261 | |
| Domain | - | 9.06e-04 | 5 | 180 | 2 | 3.30.1360.120 | |
| Domain | TrmE/GcvT_dom1 | 9.06e-04 | 5 | 180 | 2 | IPR027266 | |
| Domain | YD | 9.06e-04 | 5 | 180 | 2 | IPR006530 | |
| Domain | Glyco_hydro_57/38_cen | 9.06e-04 | 5 | 180 | 2 | IPR028995 | |
| Domain | Glyco_hydro_38 | 9.06e-04 | 5 | 180 | 2 | PF01074 | |
| Domain | GCV_T_C | 9.06e-04 | 5 | 180 | 2 | IPR013977 | |
| Domain | - | 9.06e-04 | 5 | 180 | 2 | 1.20.1270.50 | |
| Domain | - | 9.06e-04 | 5 | 180 | 2 | 3.20.110.10 | |
| Domain | GCV_T_C | 9.06e-04 | 5 | 180 | 2 | PF08669 | |
| Domain | Alpha-mann_mid | 9.06e-04 | 5 | 180 | 2 | SM00872 | |
| Domain | Glyco_hydro_38_N | 9.06e-04 | 5 | 180 | 2 | IPR000602 | |
| Domain | Glyco_hydro_38/57_N | 9.06e-04 | 5 | 180 | 2 | IPR027291 | |
| Domain | GCV_T_N | 9.06e-04 | 5 | 180 | 2 | IPR006222 | |
| Domain | FATC | 9.06e-04 | 5 | 180 | 2 | PF02260 | |
| Domain | Glyco_hydro_38_cen | 9.06e-04 | 5 | 180 | 2 | IPR015341 | |
| Domain | Glyco_hydro_38C | 9.06e-04 | 5 | 180 | 2 | PF07748 | |
| Domain | 6-blade_b-propeller_TolB-like | 9.93e-04 | 46 | 180 | 4 | IPR011042 | |
| Domain | - | 1.03e-03 | 21 | 180 | 3 | 2.60.60.20 | |
| Domain | CRAL_TRIO | 1.03e-03 | 21 | 180 | 3 | PF00650 | |
| Domain | PLAT | 1.03e-03 | 21 | 180 | 3 | PF01477 | |
| Domain | PLAT/LH2_dom | 1.03e-03 | 21 | 180 | 3 | IPR001024 | |
| Domain | PLAT | 1.03e-03 | 21 | 180 | 3 | PS50095 | |
| Domain | LDLRA_1 | 1.17e-03 | 48 | 180 | 4 | PS01209 | |
| Domain | LDLRA_2 | 1.26e-03 | 49 | 180 | 4 | PS50068 | |
| Domain | PbH1 | 1.35e-03 | 6 | 180 | 2 | SM00710 | |
| Domain | FAT | 1.35e-03 | 6 | 180 | 2 | PS51189 | |
| Domain | FATC | 1.35e-03 | 6 | 180 | 2 | PS51190 | |
| Domain | FATC_dom | 1.35e-03 | 6 | 180 | 2 | IPR003152 | |
| Domain | PbH1 | 1.35e-03 | 6 | 180 | 2 | IPR006626 | |
| Domain | PIK_FAT | 1.35e-03 | 6 | 180 | 2 | IPR014009 | |
| Domain | FATC | 1.35e-03 | 6 | 180 | 2 | SM01343 | |
| Domain | - | 1.35e-03 | 23 | 180 | 3 | 3.40.525.10 | |
| Domain | Spectrin | 1.35e-03 | 23 | 180 | 3 | PF00435 | |
| Domain | WD_REPEATS_1 | 1.54e-03 | 278 | 180 | 9 | PS00678 | |
| Domain | WD_REPEATS_2 | 1.58e-03 | 279 | 180 | 9 | PS50082 | |
| Domain | WD_REPEATS_REGION | 1.58e-03 | 279 | 180 | 9 | PS50294 | |
| Domain | SEC14 | 1.73e-03 | 25 | 180 | 3 | SM00516 | |
| Domain | Glyco_hydro/deAcase_b/a-brl | 1.88e-03 | 7 | 180 | 2 | IPR011330 | |
| Domain | LIPASE_SER | 1.94e-03 | 26 | 180 | 3 | PS00120 | |
| Domain | CRAL_TRIO | 2.17e-03 | 27 | 180 | 3 | PS50191 | |
| Domain | - | 2.26e-03 | 95 | 180 | 5 | 2.60.120.200 | |
| Domain | CRAL-TRIO_dom | 2.42e-03 | 28 | 180 | 3 | IPR001251 | |
| Pubmed | ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1. | COL4A2 SEMA3F ABCC1 FAT4 MAN2A1 MAN2B1 CLSTN1 ADAM10 NOMO1 FZD6 MST1R MET FOXRED2 TENM3 LRP10 NOMO2 NEGR1 MRC2 LRP11 LPL SLC39A6 TTC17 TMEM131 LTBP3 ATM TAP2 ADGRA3 MGRN1 | 4.25e-11 | 1201 | 183 | 28 | 35696571 |
| Pubmed | CEACAM5 KALRN PSG4 SPEG OBSCN IGDCC3 CADM2 NEGR1 LSAMP PSG8 ADGRA3 | 1.13e-09 | 162 | 183 | 11 | 25826454 | |
| Pubmed | COL4A2 SMG1 STAM2 STBD1 MAN2B1 UBR4 SMURF1 SPART NOMO1 TENM3 PKD1 MACF1 ZNF76 LTBP3 GPNMB SPRTN NOMO3 | 1.83e-08 | 591 | 183 | 17 | 15231748 | |
| Pubmed | 1.43e-07 | 3 | 183 | 3 | 36011023 | ||
| Pubmed | Silencing of nodal modulator 1 inhibits the differentiation of P19 cells into cardiomyocytes. | 1.43e-07 | 3 | 183 | 3 | 25576386 | |
| Pubmed | Changes in melatonin receptor expression in a murine model of glaucoma. | 5.71e-07 | 4 | 183 | 3 | 32818016 | |
| Pubmed | Establishment of a conditional Nomo1 mouse model by CRISPR/Cas9 technology. | 5.71e-07 | 4 | 183 | 3 | 31833031 | |
| Pubmed | 5.71e-07 | 4 | 183 | 3 | 9267806 | ||
| Pubmed | A BioID-Derived Proximity Interactome for SARS-CoV-2 Proteins. | SMG1 ABCC1 VPS11 STXBP5 SYNE1 SPART ARHGAP1 AAAS PTPN13 TENM3 NOMO2 NFKB2 MACF1 ASB1 TTC17 GPNMB | 1.49e-06 | 719 | 183 | 16 | 35337019 |
| Pubmed | A ciliopathy complex at the transition zone protects the cilia as a privileged membrane domain. | 1.66e-06 | 38 | 183 | 5 | 22179047 | |
| Pubmed | COL4A2 MAN2B1 CKAP5 ADAM10 NOMO1 MET FOXRED2 NOMO2 MRC2 TTC17 TMEM131 LTBP3 NOMO3 MGRN1 | 5.13e-06 | 613 | 183 | 14 | 22268729 | |
| Pubmed | Quantitative Proteomics Links the LRRC59 Interactome to mRNA Translation on the ER Membrane. | ABCC1 STBD1 CKAP5 TNFRSF11A LARP4 FZD6 COLEC12 AAAS TMEM131 EIF2A CNOT1 | 5.39e-06 | 375 | 183 | 11 | 32788342 |
| Pubmed | Nicalin and its binding partner Nomo are novel Nodal signaling antagonists. | 7.87e-06 | 8 | 183 | 3 | 15257293 | |
| Pubmed | TPP2 UBR4 ARHGAP1 PTPN13 TENM3 PI4KA MTNR1A MTNR1B SLC39A6 MACF1 | 8.87e-06 | 322 | 183 | 10 | 26514267 | |
| Pubmed | A dual-strategy expression screen for candidate connectivity labels in the developing thalamus. | 8.99e-06 | 91 | 183 | 6 | 28558017 | |
| Pubmed | Genome duplications and other features in 12 Mb of DNA sequence from human chromosome 16p and 16q. | 9.58e-06 | 92 | 183 | 6 | 10493829 | |
| Pubmed | BTBD8 STXBP5 SYNE1 SPEG CKAP5 SMURF1 TENM2 TENM3 NEGR1 MACF1 ASB1 | 1.16e-05 | 407 | 183 | 11 | 12693553 | |
| Pubmed | Substrate-driven assembly of a translocon for multipass membrane proteins. | 1.18e-05 | 9 | 183 | 3 | 36261522 | |
| Pubmed | COL4A2 STAM2 PDPR STBD1 SYNE1 UBR4 SPART SPG11 NOMO1 ARHGAP1 MET PTPN13 NOMO2 PI4KA TUBGCP3 SLC39A6 MACF1 TTC17 TMEM131 ATM EIF2A DEPDC1B | 1.28e-05 | 1487 | 183 | 22 | 33957083 | |
| Pubmed | DOCK3 KALRN FOLH1 SYNE1 UBR4 CKAP5 CHD9 DCN ARHGAP1 PTPN13 NOMO2 PKD1 LRP2 MACF1 DLG2 ZNF76 TTC17 TMEM131 LTBP3 ATM | 1.59e-05 | 1285 | 183 | 20 | 35914814 | |
| Pubmed | Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly. | 2.29e-05 | 11 | 183 | 3 | 20427287 | |
| Pubmed | Meta-analysis of genome-wide association data of bipolar disorder and major depressive disorder. | 2.29e-05 | 11 | 183 | 3 | 20351715 | |
| Pubmed | An ER translocon for multi-pass membrane protein biogenesis. | 2.29e-05 | 11 | 183 | 3 | 32820719 | |
| Pubmed | 2.69e-05 | 33 | 183 | 4 | 30783098 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 22171046 | ||
| Pubmed | Ron kinase transphosphorylation sustains MET oncogene addiction. | 2.75e-05 | 2 | 183 | 2 | 21212418 | |
| Pubmed | Role of candidate genes in the lipid responses to intensified treatment in Type 2 diabetes. | 2.75e-05 | 2 | 183 | 2 | 16419488 | |
| Pubmed | Human gastroenteropancreatic expression of melatonin and its receptors MT1 and MT2. | 2.75e-05 | 2 | 183 | 2 | 25822611 | |
| Pubmed | Melatonin transmits photoperiodic signals through the MT1 melatonin receptor. | 2.75e-05 | 2 | 183 | 2 | 19261884 | |
| Pubmed | Lipoprotein lipase and endothelial lipase in human testis and in germ cell neoplasms. | 2.75e-05 | 2 | 183 | 2 | 19780863 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 32962738 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 24365461 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 31565865 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 24157813 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 36892670 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 32324988 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 24117008 | ||
| Pubmed | Heteromeric MT1/MT2 melatonin receptors modulate photoreceptor function. | 2.75e-05 | 2 | 183 | 2 | 24106342 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 14634011 | ||
| Pubmed | Modulation of dendritic cell trafficking to and from the airways. | 2.75e-05 | 2 | 183 | 2 | 16517726 | |
| Pubmed | RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells. | 2.75e-05 | 2 | 183 | 2 | 28440432 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 12915129 | ||
| Pubmed | Cyclical regulation of GnRH gene expression in GT1-7 GnRH-secreting neurons by melatonin. | 2.75e-05 | 2 | 183 | 2 | 11606436 | |
| Pubmed | MET and MST1R as prognostic factors for classical Hodgkin's lymphoma. | 2.75e-05 | 2 | 183 | 2 | 23558571 | |
| Pubmed | hSMG-1 and ATM sequentially and independently regulate the G1 checkpoint during oxidative stress. | 2.75e-05 | 2 | 183 | 2 | 18332866 | |
| Pubmed | MT1 and MT2 melatonin receptors play opposite roles in brain cancer progression. | 2.75e-05 | 2 | 183 | 2 | 33392634 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 8923472 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 31698983 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 12088876 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 18501512 | ||
| Pubmed | Melatonin pathway genes and breast cancer risk among Chinese women. | 2.75e-05 | 2 | 183 | 2 | 22138747 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 30903623 | ||
| Pubmed | Removal of melatonin receptor type 1 induces insulin resistance in the mouse. | 2.75e-05 | 2 | 183 | 2 | 20168308 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 16959416 | ||
| Pubmed | Ligation of erythrocyte CR1 induces its clustering in complex with scaffolding protein FAP-1. | 2.75e-05 | 2 | 183 | 2 | 18684861 | |
| Pubmed | Melatonin MT1 and MT2 receptor expression in Parkinson's disease. | 2.75e-05 | 2 | 183 | 2 | 20110911 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 17093291 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 22686298 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 17356047 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 18621029 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 32430930 | ||
| Pubmed | Truncated apo B-70.5-containing lipoproteins bind to megalin but not the LDL receptor. | 2.75e-05 | 2 | 183 | 2 | 10330424 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 34634697 | ||
| Pubmed | Localization of melatonin and its receptors (melatonin 1a and 1b receptors) in the mouse inner ear. | 2.75e-05 | 2 | 183 | 2 | 31561736 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 25876057 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 23073388 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 19706469 | ||
| Pubmed | Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. | 2.75e-05 | 2 | 183 | 2 | 31584608 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 33802342 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 25352055 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 26519818 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 20711474 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 20099167 | ||
| Pubmed | MTNR1A and MTNR1B gene polymorphisms in women with gestational diabetes. | 2.75e-05 | 2 | 183 | 2 | 28084098 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 11940583 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 23745832 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 7686151 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 26079448 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 30664204 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 15185077 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 26824606 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 15630456 | ||
| Pubmed | Evidence for feedback control of pineal melatonin secretion. | 2.75e-05 | 2 | 183 | 2 | 23528860 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 16098099 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 21362461 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 16049329 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 27919987 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 23333399 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 20726823 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 29374562 | ||
| Pubmed | Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. | 2.75e-05 | 2 | 183 | 2 | 32040955 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 34545688 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 22017484 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 15266022 | ||
| Pubmed | Melatonin receptor mRNA expression in human granulosa cells. | 2.75e-05 | 2 | 183 | 2 | 10612428 | |
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 25874493 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 36293397 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 22357919 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 18341518 | ||
| Pubmed | 2.75e-05 | 2 | 183 | 2 | 26189249 | ||
| Interaction | PSG8 interactions | 6.76e-08 | 41 | 179 | 7 | int:PSG8 | |
| Interaction | SFTPC interactions | MAN2A1 SLC39A4 ADAM10 NOMO1 FZD6 MST1R MET PHC3 TTC17 TMEM131 NOMO3 ADGRA3 MGRN1 | 9.86e-08 | 222 | 179 | 13 | int:SFTPC |
| Interaction | SDF2L1 interactions | MAN2B1 CLSTN1 ADAM10 MST1R MET FOXRED2 SLC39A6 TTC17 TMEM131 ROS1 PSG8 SPRTN TCTN1 NOMO3 MGRN1 | 2.00e-07 | 322 | 179 | 15 | int:SDF2L1 |
| Interaction | TRGV3 interactions | 5.49e-07 | 55 | 179 | 7 | int:TRGV3 | |
| Interaction | FBXO2 interactions | MAN2B1 CDHR2 PRAMEF2 ADAM10 NOMO1 MET COLEC12 TENM3 LRP10 MRC2 LRP2 TTC17 TMEM131 NOMO3 ADGRA3 MGRN1 | 8.61e-07 | 411 | 179 | 16 | int:FBXO2 |
| Interaction | BRICD5 interactions | MAN2A1 CLSTN1 ADAM10 NOMO1 MST1R MET LRP11 TTC17 TMEM131 NOMO3 ADGRA3 | 1.34e-06 | 194 | 179 | 11 | int:BRICD5 |
| Interaction | PRG2 interactions | MAN2A1 MAN2B1 CLSTN1 ADAM10 NOMO1 MST1R FOXRED2 GID4 SLC39A6 TTC17 TMEM131 LTBP3 | 9.67e-06 | 285 | 179 | 12 | int:PRG2 |
| Interaction | BTNL2 interactions | 1.04e-05 | 155 | 179 | 9 | int:BTNL2 | |
| Interaction | HLA-G interactions | 1.06e-05 | 118 | 179 | 8 | int:HLA-G | |
| Interaction | MMP2 interactions | 1.25e-05 | 87 | 179 | 7 | int:MMP2 | |
| Interaction | GML interactions | 1.25e-05 | 58 | 179 | 6 | int:GML | |
| Interaction | TMEM106A interactions | SLC39A4 CLSTN1 ADAM10 NOMO1 MST1R SLC39A6 TTC17 TMEM131 ADGRA3 MGRN1 | 2.24e-05 | 214 | 179 | 10 | int:TMEM106A |
| Interaction | GPIHBP1 interactions | 2.52e-05 | 133 | 179 | 8 | int:GPIHBP1 | |
| Interaction | NAAA interactions | MAN2A1 ADAM10 PPOX NOMO1 MST1R FOXRED2 LIPG TTC17 POLD3 TCTN1 | 2.84e-05 | 220 | 179 | 10 | int:NAAA |
| Interaction | SCGB2A2 interactions | 3.18e-05 | 223 | 179 | 10 | int:SCGB2A2 | |
| Interaction | TMPRSS13 interactions | 4.51e-05 | 106 | 179 | 7 | int:TMPRSS13 | |
| Interaction | LRRTM1 interactions | 5.93e-05 | 47 | 179 | 5 | int:LRRTM1 | |
| Interaction | KLK15 interactions | 6.25e-05 | 151 | 179 | 8 | int:KLK15 | |
| Interaction | C3orf18 interactions | 7.58e-05 | 115 | 179 | 7 | int:C3orf18 | |
| Interaction | DNASE1L1 interactions | 9.92e-05 | 120 | 179 | 7 | int:DNASE1L1 | |
| Interaction | LLCFC1 interactions | 1.05e-04 | 121 | 179 | 7 | int:LLCFC1 | |
| Interaction | IL5RA interactions | 1.22e-04 | 124 | 179 | 7 | int:IL5RA | |
| Interaction | C1orf54 interactions | 1.26e-04 | 167 | 179 | 8 | int:C1orf54 | |
| Interaction | TAFA4 interactions | 1.27e-04 | 55 | 179 | 5 | int:TAFA4 | |
| GeneFamily | Blood group antigens|CD molecules|I-set domain containing|Immunoglobulin like domain containing | CEACAM5 KALRN SPEG OBSCN IGDCC3 CADM2 NEGR1 LSAMP ADGRA3 MYBPC2 | 2.03e-07 | 161 | 127 | 10 | 593 |
| GeneFamily | Cadherin related | 5.15e-06 | 17 | 127 | 4 | 24 | |
| GeneFamily | Melatonin receptors | 4.90e-05 | 2 | 127 | 2 | 209 | |
| GeneFamily | CD molecules|V-set domain containing|Pregnancy specific glycoproteins | 5.36e-05 | 11 | 127 | 3 | 1315 | |
| GeneFamily | Low density lipoprotein receptors | 9.20e-05 | 13 | 127 | 3 | 634 | |
| GeneFamily | Lipases|Arylacetamide deacetylase family | 4.73e-04 | 22 | 127 | 3 | 464 | |
| GeneFamily | Mannosidases alpha class 2 | 4.83e-04 | 5 | 127 | 2 | 1194 | |
| GeneFamily | I-set domain containing|IgLON cell adhesion molecules | 4.83e-04 | 5 | 127 | 2 | 1052 | |
| GeneFamily | WD repeat domain containing | 5.31e-04 | 262 | 127 | 8 | 362 | |
| GeneFamily | Receptor Tyrosine Kinases|CD molecules | 2.77e-03 | 40 | 127 | 3 | 321 | |
| Coexpression | MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP | 5.19e-06 | 182 | 181 | 9 | MM993 | |
| Coexpression | BOQUEST_STEM_CELL_UP | 1.47e-05 | 261 | 181 | 10 | M1834 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | FAT4 KALRN FOLH1 OBSCN APOB PKHD1L1 CADM2 SORCS1 ADAMTS16 LRP2 ADAMTS20 ROS1 HYDIN | 8.54e-13 | 184 | 183 | 13 | 2cbed6462fea2622871bb7e49b0df3d984239281 |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | FAT4 KALRN FOLH1 OBSCN APOB PKHD1L1 CADM2 SORCS1 ADAMTS16 LRP2 ADAMTS20 ROS1 HYDIN | 8.54e-13 | 184 | 183 | 13 | ea7a7e2bac46d4d2c31a5d576b38a032b5335062 |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | FAT4 KALRN FOLH1 OBSCN APOB PKHD1L1 CADM2 SORCS1 ADAMTS16 LRP2 ADAMTS20 ROS1 HYDIN | 8.54e-13 | 184 | 183 | 13 | 2b19a8c5f823e00812908b23e66bb4e563278aff |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_adventitial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | COL4A2 FAT4 SYNE1 AOX1 CLSTN2 DCN COLEC12 THBS2 GPC3 NEGR1 MRC2 LSAMP GPNMB | 2.47e-12 | 200 | 183 | 13 | 0c25d56292b9e5fefa4521b72635449be1ffd6fe |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | COL4A2 FAT4 SYNE1 AOX1 DCN COLEC12 THBS2 GPC3 NEGR1 MRC2 LSAMP GPNMB | 4.48e-11 | 200 | 183 | 12 | b4ccffdd79526c85e5273d27b668dbddcddba1ee |
| ToppCell | Tracheal-NucSeq-Stromal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | COL4A2 FAT4 SYNE1 AOX1 DCN COLEC12 THBS2 TENM3 NEGR1 MRC2 DLG2 LSAMP | 4.48e-11 | 200 | 183 | 12 | c318d14bd6fd6f42c597eb55ac9e2f48008aeb9b |
| ToppCell | Fetal_29-31_weeks-Mesenchymal|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | COL4A2 DOK6 FAT4 KALRN DCN COLEC12 THBS2 GPC3 TENM3 MRC2 LSAMP | 6.67e-10 | 198 | 183 | 11 | 21cf4d81386761d09d0f6829c01c198e5524176d |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 7.19e-09 | 191 | 183 | 10 | 08720998aa55131d7377c4c67c4c935865bd7d79 | |
| ToppCell | COVID-19-Fibroblasts|COVID-19 / group, cell type (main and fine annotations) | 9.66e-09 | 197 | 183 | 10 | fb847f2277609c31fffcdf49517243ce0684facf | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 9.66e-09 | 197 | 183 | 10 | 11a4c417f035e554431a8f03be13b5eefa3530c0 | |
| ToppCell | COVID-19-lung-Fibroblast|lung / Disease (COVID-19 only), tissue and cell type | 1.01e-08 | 198 | 183 | 10 | df3de77216f5c5d6141ec44d01c56b942f611838 | |
| ToppCell | 5'-Adult-Distal_Rectal-Mesenchymal-fibroblastic-mLN_Stroma_(FMO2+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.77e-08 | 185 | 183 | 9 | 9faa35ceb89ccd2979072286f063687c9f846ce3 | |
| ToppCell | 5'-Adult-Appendix-Mesenchymal-fibroblastic-mLN_Stroma_(FMO2+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 8.13e-08 | 186 | 183 | 9 | 7582b5154d8e5a4434817b5ab77a10b789ea2288 | |
| ToppCell | nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.02e-07 | 191 | 183 | 9 | 6688cee34beee4f151ac17fccbc9c26a9aad72e1 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.17e-07 | 194 | 183 | 9 | 011e14d9ed1393275f892060e7708ffadcd0767f | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.17e-07 | 194 | 183 | 9 | 60622bd2f75bfe4c37f721cb12f03dab33f2f58d | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 1.27e-07 | 196 | 183 | 9 | 1450cb69c5bf469e97c03bf1890f6f7c54165b8a | |
| ToppCell | COVID-19-Fibroblasts-Intermediate_pathological_FB|COVID-19 / group, cell type (main and fine annotations) | 1.33e-07 | 197 | 183 | 9 | f1c8936986123a3151140c374fcd62d6705c530b | |
| ToppCell | 5'-Adult-Appendix-Mesenchymal-fibroblastic|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.33e-07 | 197 | 183 | 9 | ab5d3ebc73bd7cfc64381d14b92878b370205186 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 1.39e-07 | 198 | 183 | 9 | 17dc055e2a289496d9c5cdbf3297bdf906dc6d22 | |
| ToppCell | Mesenchymal|World / Lineage, Cell type, age group and donor | 1.45e-07 | 199 | 183 | 9 | 4bac110c2b3609f6ee5d0e3275da0824a6240270 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.45e-07 | 199 | 183 | 9 | 30d3e8c0681ec11f86dd38c5f48d21187a1b4f90 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.45e-07 | 199 | 183 | 9 | e1849505b92820a219c5a2c35492bdd55579fb48 | |
| ToppCell | wk_15-18-Mesenchymal-Fibroblast-Alveolar_fibro|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 1.45e-07 | 199 | 183 | 9 | 6bce8e65859a35cfea1c210f9c9765952d492ed2 | |
| ToppCell | Bronchial-NucSeq-Stromal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.51e-07 | 200 | 183 | 9 | 389cc775c8419d90fb77cd794376d2160a7bf44e | |
| ToppCell | Parenchymal-NucSeq-Stromal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.51e-07 | 200 | 183 | 9 | cf433f9b43d7db07acaf70e060f8f77c974e72f3 | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.51e-07 | 200 | 183 | 9 | cae972324d1dfea6efeaf6013f265c7c6bb48db4 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.51e-07 | 200 | 183 | 9 | 311fab076f2ceb258e3970eb21e39344b894042a | |
| ToppCell | facs-Pancreas-Exocrine-18m-Mesenchymal|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.62e-07 | 181 | 183 | 8 | 269b39ac65790061d54eab47a8eeb024403f0348 | |
| ToppCell | facs-Pancreas-Exocrine-18m-Mesenchymal-pancreatic_stellate_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.62e-07 | 181 | 183 | 8 | cd4f744b6b64ba6c22ec07afd1d3058a2546909d | |
| ToppCell | facs-Pancreas-Exocrine-18m-Mesenchymal-pancreatic_stellate_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.62e-07 | 181 | 183 | 8 | c8395ae872aa80b3ae1ab7c53e57b3ca15aeb0e2 | |
| ToppCell | TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1|TCGA-Pancreas / Sample_Type by Project: Shred V9 | 1.06e-06 | 186 | 183 | 8 | 03db813598b67b1e08f759758a1c2023396921fa | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 1.10e-06 | 187 | 183 | 8 | a9316e2818217ec5feae9cf8816f7249803caee6 | |
| ToppCell | Control-Fibroblasts-Alveolar_FB|Control / group, cell type (main and fine annotations) | 1.10e-06 | 187 | 183 | 8 | 92d468dde81125d51daf7abd4703741abe1ab91c | |
| ToppCell | droplet-Pancreas-Exocrine-18m-Mesenchymal-pancreatic_stellate_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.10e-06 | 187 | 183 | 8 | 4e553721fa5598cb211f44e3226280b7e6885484 | |
| ToppCell | droplet-Pancreas-Exocrine-18m-Mesenchymal|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.10e-06 | 187 | 183 | 8 | d36e7fc6125e7a4310499365022d38f34b757a73 | |
| ToppCell | droplet-Pancreas-Exocrine-18m-Mesenchymal-pancreatic_stellate_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.10e-06 | 187 | 183 | 8 | 827eae63fabf6892a82ce7779b5f395958d3d628 | |
| ToppCell | facs-Skin-nan-18m-Epithelial-Basal_IFE|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.19e-06 | 189 | 183 | 8 | 6c71e81373cb7822de23c193a6350b6df9f567bc | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.24e-06 | 190 | 183 | 8 | 1121eb607a984c59fbffe7220837fc178745aa55 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.24e-06 | 190 | 183 | 8 | 2306aa9dbeaef3be8484a5b236605de23cd75d4c | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.24e-06 | 190 | 183 | 8 | 048b581e3f7ea9fc2f87c0532974bba85c7292c2 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.24e-06 | 190 | 183 | 8 | 1f83f7f24288a3b9ab33c2e113e845dba96adc8a | |
| ToppCell | Control-Fibroblasts|Control / group, cell type (main and fine annotations) | 1.24e-06 | 190 | 183 | 8 | 3a42a9b98d954685d38a741f44545898d0e3e9ce | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.29e-06 | 191 | 183 | 8 | b13229bb7f3713a392271aaf5dbae3edd1b9fe5a | |
| ToppCell | nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.34e-06 | 192 | 183 | 8 | 99ce9e3c4c50cf64ebb62145f2b5420efa0db309 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.34e-06 | 192 | 183 | 8 | e0f4e4470a71bfa81d9dcd8594e5f82aafc24f81 | |
| ToppCell | severe-low-quality_cells|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.40e-06 | 193 | 183 | 8 | 9337bc93e3904c7fc7c93c328518bcd6453b1e8c | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.40e-06 | 193 | 183 | 8 | 99525545552b371c86b18b6ea6f4897dc6e9a9ec | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.40e-06 | 193 | 183 | 8 | fb28717fadd06c3840636d25409ce80c9254bd34 | |
| ToppCell | Mesenchymal-matrix_fibroblast_1_cell|World / Lineage, Cell type, age group and donor | 1.40e-06 | 193 | 183 | 8 | acad568621ed677031797b8c2e34dafea798d681 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 1.45e-06 | 194 | 183 | 8 | b1bb0f846d2865efdd9bc8842b16b9d069785882 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.45e-06 | 194 | 183 | 8 | 6e13549f697f7478b34fe71f7dd9d63c5d3db22e | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.45e-06 | 194 | 183 | 8 | 89b706af2b25991fc2707eb24f49ba6ff3ae01f7 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 1.51e-06 | 195 | 183 | 8 | 1cdf5f296029ae424d9dba42e86a6d111e4896e6 | |
| ToppCell | RA-02._Fibroblast_II|RA / Chamber and Cluster_Paper | 1.51e-06 | 195 | 183 | 8 | 6a02ebbeb3199447ddce64d92d8809436e040eba | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.57e-06 | 196 | 183 | 8 | a12dd986df65c36f248cf10815c3b8b6238613b0 | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.57e-06 | 196 | 183 | 8 | 42e9828222a9663525d571633e8a454c30bfa7f8 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.57e-06 | 196 | 183 | 8 | 3e6803587d8566fd08cb8b290be3b6461743d79c | |
| ToppCell | nucseq-Mesenchymal-Fibroblastic|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.57e-06 | 196 | 183 | 8 | 7d8505dac15fa59935ccf592afc54b04c4c6554f | |
| ToppCell | RA-02._Fibroblast_II|World / Chamber and Cluster_Paper | 1.57e-06 | 196 | 183 | 8 | e8cbda03837f1f26470a9d93aa7fdaa04e08e38a | |
| ToppCell | LPS_IL1RA_TNF|World / Treatment groups by lineage, cell group, cell type | 1.63e-06 | 197 | 183 | 8 | 0a6550dce156fc81f15b1e7830d331ca50d87d06 | |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_myofibroblast|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.63e-06 | 197 | 183 | 8 | 0dd71e399f253787fa546a7e90c5373180b89ffd | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 1.63e-06 | 197 | 183 | 8 | 31a1852911bda38543916585fda34255fd62a134 | |
| ToppCell | severe-low-quality_cells|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.63e-06 | 197 | 183 | 8 | 57ebd552f10d6278623b52a3d484d4b91ae1d028 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.63e-06 | 197 | 183 | 8 | 6d027119a5f7ca2aac1b10837e43f9a2bb54db85 | |
| ToppCell | COPD-Stromal-Myofibroblast|World / Disease state, Lineage and Cell class | 1.63e-06 | 197 | 183 | 8 | d51f484b4e01ac64233950d0b97fa88825ea1dbb | |
| ToppCell | 5'-Adult-Appendix-Mesenchymal|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.63e-06 | 197 | 183 | 8 | b11a5d909942a4299cbc0b27332b1a3f66f3bccd | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.63e-06 | 197 | 183 | 8 | b349f8e96d61a4c296af64711e11fc44459a9413 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 1.63e-06 | 197 | 183 | 8 | 0034bae02ee7fcfea520d453ca3c842ab6963b12 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.63e-06 | 197 | 183 | 8 | c2e390653d5dee7e731c1840cfdab41987dede9b | |
| ToppCell | nucseq-Mesenchymal|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.69e-06 | 198 | 183 | 8 | 8f52243ca8b9ba68a75ae411506a3a6de258eb97 | |
| ToppCell | mild-low-quality_cells|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.75e-06 | 199 | 183 | 8 | f0b0097df0026496470a80d8cc9375ffd8389b00 | |
| ToppCell | Fetal_29-31_weeks|World / Lineage, Cell type, age group and donor | 1.75e-06 | 199 | 183 | 8 | 5b9d355795dd03a22f0961dfd143425c367a4654 | |
| ToppCell | LPS_only-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_only / Treatment groups by lineage, cell group, cell type | 1.75e-06 | 199 | 183 | 8 | fde2b65afde69f402f1b7b056eaa266e9fd5b227 | |
| ToppCell | LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 1.75e-06 | 199 | 183 | 8 | a7dd94b172c973a131a6792f8ccd9bfe44d984ac | |
| ToppCell | PCW_10-12-Mesenchymal|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 1.75e-06 | 199 | 183 | 8 | a09292de4c4447b8eee55d401808e43b817321cc | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.82e-06 | 200 | 183 | 8 | 9b0916d8d07ac2bf1739f7be5296bf77ffee6094 | |
| ToppCell | wk_20-22-Mesenchymal-Fibroblast-Alveolar_fibro|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 1.82e-06 | 200 | 183 | 8 | 0ed49c2177b58269ff7653db6be7d68633a5d34a | |
| ToppCell | Control_saline-Mesenchymal_myocytic-Myofibroblastic-MatrixFB_->_Myofibroblast|Control_saline / Treatment groups by lineage, cell group, cell type | 1.82e-06 | 200 | 183 | 8 | a799fc7bb83ad0524362cb5010df949741fb7bf3 | |
| ToppCell | cellseq2-Mesenchymal-Fibroblastic-Fibroblastic_1-AF2|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.82e-06 | 200 | 183 | 8 | 44317fbf4d1480a37b50ab2777bf1a3e4fc0c05f | |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.82e-06 | 200 | 183 | 8 | 3dd022e974fec7013ba18f333da63f58fbf2dd7c | |
| ToppCell | LPS_only-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_only / Treatment groups by lineage, cell group, cell type | 1.82e-06 | 200 | 183 | 8 | a7ef7022b8efcaedb7319b0b43d8c4e99d788fe2 | |
| ToppCell | cellseq2-Mesenchymal-Fibroblastic|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.82e-06 | 200 | 183 | 8 | 1c10597edd532bf172ca09870a937d35e2585081 | |
| ToppCell | 5'-Adult-LargeIntestine-Mesenchymal|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.82e-06 | 200 | 183 | 8 | 5a87bb8eb1c6bd2fbc357e1528e15ba1c0051438 | |
| ToppCell | cellseq2-Mesenchymal-Fibroblastic-Fibroblastic_1|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.82e-06 | 200 | 183 | 8 | 440dda48b09c6a8581b7ca634b0d67f1ecacf65e | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 4.17e-06 | 158 | 183 | 7 | e7db0ee4740e3c7a4d97d7cd7462e2c2ab458a4b | |
| ToppCell | renal_medulla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell-Parietal_Epithelial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 4.17e-06 | 158 | 183 | 7 | d39e020c3e77eb9d3de600a171d22f94357061d4 | |
| ToppCell | 10x5'-blood-Lymphocytic_T_CD4-T_CD4/CD8|blood / Manually curated celltypes from each tissue | 4.92e-06 | 162 | 183 | 7 | b4535bcb3f469bc139e73f1122f4070013e5a1de | |
| ToppCell | P15-Mesenchymal-mesenchymal_fibroblast-mesothelial_cell_of_visceral_pleura|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 5.78e-06 | 166 | 183 | 7 | 545f6c91102568791443717e522f89cb3bd1a070 | |
| ToppCell | droplet-Heart-HEART-1m-Endothelial-leukocyte|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.57e-06 | 173 | 183 | 7 | 9dc7746a84f0e268a7c061e1bbcd5e31903034dc | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 8.79e-06 | 177 | 183 | 7 | da8802a6351d3e510822f82e2fde8a4314a2216e | |
| ToppCell | RA-01._Fibroblast_I|World / Chamber and Cluster_Paper | 1.02e-05 | 181 | 183 | 7 | 2b6ddeb53a79a658e2ba78527ff48c155b20daa6 | |
| ToppCell | 5'-Adult-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.05e-05 | 182 | 183 | 7 | 3dfa9187e9d2bab1d199079d29209c4648220ada | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-myofibroblast_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.05e-05 | 182 | 183 | 7 | ed6ae0fd8653f213fe29906a6a4e0729a62e1b75 | |
| ToppCell | facs-Thymus-Epithelium-24m-Mesenchymal-fibroblast|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.17e-05 | 185 | 183 | 7 | eaa54b76743628c89b4310be57b87fa92b75fd37 | |
| ToppCell | LPS_only-Stromal_mesenchymal-Lung_smooth_muscle-Myofibroblast|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.17e-05 | 185 | 183 | 7 | e64e8c98dd88d91f6501d3fb10b60fd2f3c90af3 | |
| ToppCell | facs-Thymus-Epithelium-24m-Mesenchymal-fibroblast|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.17e-05 | 185 | 183 | 7 | f7f4c921d248c637351e2e882589b99ba7f04b66 | |
| ToppCell | facs-Thymus-Epithelium-24m-Mesenchymal|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.17e-05 | 185 | 183 | 7 | ff38a15af3dec36d9993f06623591872b5d1da9a | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Myocytic-Myofibroblast|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.19e-05 | 123 | 183 | 6 | 87401764a073c1808f214642a9c84299c78f7ec7 | |
| ToppCell | Control-Fibroblasts-Other_FB|Control / group, cell type (main and fine annotations) | 1.26e-05 | 187 | 183 | 7 | bd3739c4a52aa1ba5deffd778e113a9800f7e158 | |
| Disease | high density lipoprotein particle size measurement | 9.56e-06 | 170 | 178 | 8 | EFO_0008592 | |
| Disease | triglycerides in very large HDL measurement | 2.06e-05 | 55 | 178 | 5 | EFO_0022324 | |
| Disease | cholesterol:total lipids ratio, low density lipoprotein cholesterol measurement | 2.83e-05 | 144 | 178 | 7 | EFO_0004611, EFO_0020943 | |
| Disease | phospholipids:total lipids ratio, intermediate density lipoprotein measurement | 5.39e-05 | 67 | 178 | 5 | EFO_0008595, EFO_0020946 | |
| Disease | very low density lipoprotein cholesterol measurement, cholesterol:total lipids ratio | 6.45e-05 | 222 | 178 | 8 | EFO_0008317, EFO_0020943 | |
| Disease | triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement | 7.09e-05 | 225 | 178 | 8 | EFO_0008317, EFO_0020947 | |
| Disease | tissue plasminogen activator measurement, coronary artery disease | 7.12e-05 | 71 | 178 | 5 | EFO_0001645, EFO_0004791 | |
| Disease | very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio | 7.34e-05 | 291 | 178 | 9 | EFO_0008317, EFO_0020946 | |
| Disease | cholesteryl esters to total lipids in small HDL percentage | 1.31e-04 | 43 | 178 | 4 | EFO_0022254 | |
| Disease | melanoma | 1.39e-04 | 248 | 178 | 8 | C0025202 | |
| Disease | Gastric Adenocarcinoma | 1.57e-04 | 45 | 178 | 4 | C0278701 | |
| Disease | cD177 antigen measurement | 1.65e-04 | 18 | 178 | 3 | EFO_0021866 | |
| Disease | very low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio | 2.13e-04 | 264 | 178 | 8 | EFO_0008317, EFO_0020944 | |
| Disease | phospholipid measurement | 2.13e-04 | 140 | 178 | 6 | EFO_0004639 | |
| Disease | cholesteryl esters to total lipids in IDL percentage | 2.37e-04 | 50 | 178 | 4 | EFO_0022247 | |
| Disease | cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement | 2.87e-04 | 276 | 178 | 8 | EFO_0004612, EFO_0020943 | |
| Disease | triglycerides:total lipids ratio, low density lipoprotein cholesterol measurement | 3.09e-04 | 150 | 178 | 6 | EFO_0004611, EFO_0020947 | |
| Disease | cholesteryl esters:total lipids ratio, intermediate density lipoprotein measurement | 4.10e-04 | 103 | 178 | 5 | EFO_0008595, EFO_0020944 | |
| Disease | late-onset Alzheimers disease | 4.18e-04 | 292 | 178 | 8 | EFO_1001870 | |
| Disease | total lipids in medium HDL measurement | 4.21e-04 | 58 | 178 | 4 | EFO_0022310 | |
| Disease | free cholesterol in medium HDL measurement | 4.21e-04 | 58 | 178 | 4 | EFO_0022267 | |
| Disease | lipoprotein measurement | 4.48e-04 | 105 | 178 | 5 | EFO_0004732 | |
| Disease | cholesterol in medium HDL measurement | 4.50e-04 | 59 | 178 | 4 | EFO_0021903 | |
| Disease | free cholesterol in HDL measurement | 5.11e-04 | 61 | 178 | 4 | EFO_0022264 | |
| Disease | phospholipids in HDL measurement | 5.11e-04 | 61 | 178 | 4 | EFO_0022293 | |
| Disease | free cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement | 5.33e-04 | 303 | 178 | 8 | EFO_0004612, EFO_0020945 | |
| Disease | cholesterol to total lipids in small LDL percentage | 5.68e-04 | 27 | 178 | 3 | EFO_0022241 | |
| Disease | cholesterol to total lipids in medium LDL percentage | 5.68e-04 | 27 | 178 | 3 | EFO_0022238 | |
| Disease | total lipids in HDL measurement | 5.78e-04 | 63 | 178 | 4 | EFO_0022307 | |
| Disease | factor VIII measurement, coronary artery disease | 6.27e-04 | 113 | 178 | 5 | EFO_0001645, EFO_0004630 | |
| Disease | cholesteryl ester measurement, high density lipoprotein cholesterol measurement | 6.45e-04 | 312 | 178 | 8 | EFO_0004612, EFO_0010351 | |
| Disease | total cholesterol measurement, high density lipoprotein cholesterol measurement | 6.87e-04 | 315 | 178 | 8 | EFO_0004574, EFO_0004612 | |
| Disease | total lipids in very large HDL measurement | 6.89e-04 | 66 | 178 | 4 | EFO_0022312 | |
| Disease | phospholipids in very large HDL measurement | 6.89e-04 | 66 | 178 | 4 | EFO_0022298 | |
| Disease | centronuclear myopathy (implicated_via_orthology) | 7.45e-04 | 7 | 178 | 2 | DOID:14717 (implicated_via_orthology) | |
| Disease | cholesterol:total lipids ratio, intermediate density lipoprotein measurement | 8.54e-04 | 121 | 178 | 5 | EFO_0008595, EFO_0020943 | |
| Disease | sleep duration, high density lipoprotein cholesterol measurement | 8.54e-04 | 121 | 178 | 5 | EFO_0004612, EFO_0005271 | |
| Disease | cholesteryl esters to total lipids in large LDL percentage | 8.57e-04 | 31 | 178 | 3 | EFO_0022249 | |
| Disease | cesarean section, Self-injurious behavior | 9.41e-04 | 32 | 178 | 3 | EFO_0009636, HP_0100716 | |
| Disease | familial hyperlipidemia (is_implicated_in) | 9.89e-04 | 8 | 178 | 2 | DOID:1168 (is_implicated_in) | |
| Disease | phospholipids in large HDL measurement | 1.01e-03 | 73 | 178 | 4 | EFO_0022190 | |
| Disease | total lipids in large HDL | 1.06e-03 | 74 | 178 | 4 | EFO_0022189 | |
| Disease | phosphatidylcholine 38:2 measurement | 1.23e-03 | 35 | 178 | 3 | EFO_0010384 | |
| Disease | tissue plasminogen activator measurement | 1.27e-03 | 9 | 178 | 2 | EFO_0004791 | |
| Disease | lifestyle measurement, systolic blood pressure | 1.27e-03 | 9 | 178 | 2 | EFO_0006335, EFO_0010724 | |
| Disease | coenzyme Q10 measurement | 1.33e-03 | 36 | 178 | 3 | EFO_0007836 | |
| Disease | triacylglycerol 52:4 measurement | 1.33e-03 | 36 | 178 | 3 | EFO_0010416 | |
| Disease | myocardial infarction | 1.35e-03 | 350 | 178 | 8 | EFO_0000612 | |
| Disease | free cholesterol in large HDL measurement | 1.35e-03 | 79 | 178 | 4 | EFO_0022157 | |
| Disease | metabolic syndrome | 1.39e-03 | 200 | 178 | 6 | EFO_0000195 | |
| Disease | cholesterol in large HDL measurement | 1.42e-03 | 80 | 178 | 4 | EFO_0021900 | |
| Disease | free cholesterol to total lipids in large VLDL percentage | 1.44e-03 | 37 | 178 | 3 | EFO_0022281 | |
| Disease | cholesteryl esters to total lipids in medium LDL percentage | 1.44e-03 | 37 | 178 | 3 | EFO_0022252 | |
| Disease | level of Triacylglycerol (51:3) in blood serum | 1.58e-03 | 10 | 178 | 2 | OBA_2045163 | |
| Disease | degree of unsaturation measurement | 1.68e-03 | 39 | 178 | 3 | EFO_0022261 | |
| Disease | Hypercholesterolemia | 1.68e-03 | 39 | 178 | 3 | C0020443 | |
| Disease | Inherited neuropathies | 1.81e-03 | 40 | 178 | 3 | C0598589 | |
| Disease | cholesteryl ester 18:3 measurement | 1.81e-03 | 40 | 178 | 3 | EFO_0010346 | |
| Disease | pulse pressure measurement | STAM2 PDPR PHF19 NBEAL1 FOLH1 CKAP5 LARP4 CADM2 MET THBS2 MRC2 RPTOR LPL PKD1 MTNR1B LTBP3 CNOT1 HYDIN | 1.96e-03 | 1392 | 178 | 18 | EFO_0005763 |
| Disease | cholesteryl esters to total lipids in small LDL percentage | 2.08e-03 | 42 | 178 | 3 | EFO_0022255 | |
| Disease | integral membrane protein 2B measurement | 2.30e-03 | 12 | 178 | 2 | EFO_0802634 | |
| Disease | lymphangioleiomyomatosis (is_marker_for) | 2.30e-03 | 12 | 178 | 2 | DOID:3319 (is_marker_for) | |
| Disease | age at first sexual intercourse measurement | 2.36e-03 | 383 | 178 | 8 | EFO_0009749 | |
| Disease | visual perception measurement | 2.41e-03 | 223 | 178 | 6 | EFO_0009700 | |
| Disease | low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio | 2.41e-03 | 153 | 178 | 5 | EFO_0004611, EFO_0020946 | |
| Disease | low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio | 2.41e-03 | 153 | 178 | 5 | EFO_0004611, EFO_0020944 | |
| Disease | total lipids in very small VLDL measurement | 2.54e-03 | 45 | 178 | 3 | EFO_0022156 | |
| Disease | saturated fatty acids measurement | 2.54e-03 | 45 | 178 | 3 | EFO_0022304 | |
| Disease | phospholipids:total lipids ratio | 2.63e-03 | 227 | 178 | 6 | EFO_0020946 | |
| Disease | phosphocreatine measurement | 2.70e-03 | 13 | 178 | 2 | EFO_0010521 | |
| Disease | Modic type vertebral endplate changes | 2.70e-03 | 13 | 178 | 2 | HP_0030775 | |
| Disease | Hyperlipoproteinemia Type IIb | 2.70e-03 | 13 | 178 | 2 | C1704417 | |
| Disease | phospholipids:total lipids ratio, high density lipoprotein cholesterol measurement | 2.71e-03 | 307 | 178 | 7 | EFO_0004612, EFO_0020946 | |
| Disease | small vessel stroke | 2.76e-03 | 96 | 178 | 4 | EFO_1001504 | |
| Disease | Osteosarcoma | 2.88e-03 | 47 | 178 | 3 | C0029463 | |
| Disease | Alzheimer disease, polygenic risk score | 3.08e-03 | 586 | 178 | 10 | EFO_0030082, MONDO_0004975 | |
| Disease | free cholesterol measurement, high density lipoprotein cholesterol measurement | 3.12e-03 | 315 | 178 | 7 | EFO_0004612, EFO_0008591 | |
| Disease | age at last pregnancy measurement | 3.14e-03 | 14 | 178 | 2 | EFO_0009440 | |
| Disease | Adenocarcinoma Of Esophagus | 3.14e-03 | 14 | 178 | 2 | C0279628 | |
| Disease | polycystic kidney disease (implicated_via_orthology) | 3.14e-03 | 14 | 178 | 2 | DOID:0080322 (implicated_via_orthology) | |
| Disease | coronary artery disease (is_implicated_in) | 3.20e-03 | 100 | 178 | 4 | DOID:3393 (is_implicated_in) | |
| Disease | apolipoprotein B to apolipoprotein A1 ratio | 3.24e-03 | 49 | 178 | 3 | EFO_0021897 | |
| Disease | cholesteryl esters to total lipids in small VLDL percentage | 3.24e-03 | 49 | 178 | 3 | EFO_0022256 | |
| Disease | PR interval | 3.25e-03 | 495 | 178 | 9 | EFO_0004462 | |
| Disease | phospholipid measurement, high density lipoprotein cholesterol measurement | 3.46e-03 | 321 | 178 | 7 | EFO_0004612, EFO_0004639 | |
| Disease | low density lipoprotein triglyceride measurement | 3.61e-03 | 15 | 178 | 2 | EFO_0009946 | |
| Disease | acute graft vs. host disease, donor genotype effect measurement | 3.61e-03 | 15 | 178 | 2 | EFO_0004599, EFO_0007892 | |
| Disease | triacylglycerol 52:3 measurement | 3.61e-03 | 15 | 178 | 2 | EFO_0010415 | |
| Disease | Hypertriglyceridemia | 3.61e-03 | 15 | 178 | 2 | C0020557 | |
| Disease | amenorrhea, response to antineoplastic agent | 3.61e-03 | 15 | 178 | 2 | EFO_0010269, GO_0097327 | |
| Disease | cholesterol to total lipids in small HDL percentage | 3.63e-03 | 51 | 178 | 3 | EFO_0022240 | |
| Disease | free cholesterol to total lipids in small HDL percentage | 3.63e-03 | 51 | 178 | 3 | EFO_0022285 | |
| Disease | cholesteryl esters:total lipids ratio, high density lipoprotein cholesterol measurement | 3.67e-03 | 243 | 178 | 6 | EFO_0004612, EFO_0020944 | |
| Disease | Colorectal Carcinoma | ABCC1 KALRN FOLH1 SYNE1 OBSCN APOB CLSTN2 PPOX LRP2 GPNMB POLD3 | 3.71e-03 | 702 | 178 | 11 | C0009402 |
| Disease | intraocular pressure measurement | 3.90e-03 | 509 | 178 | 9 | EFO_0004695 | |
| Disease | lipid measurement, high density lipoprotein cholesterol measurement | 4.03e-03 | 330 | 178 | 7 | EFO_0004529, EFO_0004612 | |
| Disease | triglycerides in HDL measurement | 4.05e-03 | 53 | 178 | 3 | EFO_0022317 | |
| Disease | Hyperlipoproteinemia Type IIa | 4.11e-03 | 16 | 178 | 2 | C0745103 | |
| Disease | Rolandic epilepsy | 4.11e-03 | 16 | 178 | 2 | Orphanet_1945 | |
| Disease | triglycerides in medium HDL measurement | 4.27e-03 | 54 | 178 | 3 | EFO_0022321 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| NYSSGTHNIEVIVQD | 381 | Q0P6H9 | |
| ALAAHENVVVVTIQY | 156 | P23141 | |
| QIIATYAQTELGHGT | 146 | Q99424 | |
| VTLYEHNNELVTGSS | 16 | Q9NRG9 | |
| AGVAIRSSVQTAHYV | 311 | Q9NX77 | |
| HLQGSDQEIQTYTIA | 231 | Q92556 | |
| YGTREAVIAQISSHV | 236 | O14672 | |
| QAVGIILHYSTLATV | 826 | Q8IWK6 | |
| TNINSAVYQVTVLHL | 356 | Q5MAI5 | |
| NIIQNDTGFYTLHVI | 111 | P06731 | |
| YVAVVNGHLESTQIL | 116 | Q9Y576 | |
| GLYVQSSEALHVITN | 736 | Q9UK96 | |
| HTYVLNGTFSLNLTV | 301 | Q14956 | |
| NGVLIHIQESSNYTT | 4256 | Q6V0I7 | |
| STSVVYQLLQHNIDV | 216 | A6NC57 | |
| VSIGYLLVKHSQTDQ | 1486 | P08572 | |
| SVSHIYSSQGAVVLD | 531 | P52824 | |
| FIIHNVYSVSKQGVV | 216 | Q8WUY9 | |
| VSLHAYTVTGAEQIQ | 246 | Q6MZZ7 | |
| TYHGIVTENDNTVLL | 41 | O94985 | |
| GTVYAHSTLELQTLQ | 2481 | Q96M86 | |
| GETTQITYHQLLVQV | 131 | Q9NR19 | |
| VFLYGVTTLDHSQVS | 371 | Q32M45 | |
| TSYHGVITENNDTVI | 46 | Q9H4D0 | |
| SQQVIVQGVHELYDL | 326 | Q5RIA9 | |
| HGHENITTYVLTILN | 306 | Q8TE57 | |
| VVSAHGSNLQNYILT | 271 | P59510 | |
| TLHQNSITQVSIYEV | 321 | Q92747 | |
| IEELSVVNHAYNGLT | 291 | Q06278 | |
| QILYGHTNEVLSVGI | 2486 | Q6ZS30 | |
| QASKTSIGHVVQLLY | 236 | Q5TC82 | |
| RLENITTGTYTIHAQ | 366 | P69849 | |
| GNHVEIQAAYIGTTI | 271 | Q6ZVN8 | |
| GVQAFLQTYSHEVSL | 746 | Q9Y5H2 | |
| LLVLNYGTHVTTSVD | 196 | Q2M385 | |
| VSGNKHETIYTILNQ | 656 | P0C881 | |
| VSGNKHETIYTILNQ | 656 | B2RC85 | |
| RLENITTGTYTIHAQ | 366 | Q5JPE7 | |
| GSIISAAVYLQIHTL | 141 | Q9H511 | |
| RGHIVNFITTTTSQY | 311 | Q96LI6 | |
| GTYSQVQLVQSGHEV | 16 | A0A0B4J1V7 | |
| NLIISDVTVQHSGVY | 291 | Q8IVU1 | |
| VETLSGQAVVSYHTV | 276 | Q7Z4F1 | |
| LSHLQEGTYTFQLTV | 266 | Q86VZ4 | |
| ILTVTNVTQEHFGNY | 281 | Q7Z3B1 | |
| LYHIQGIEGQSVEVS | 851 | Q16706 | |
| GTLYLTATHVIFVEN | 26 | Q9Y216 | |
| VYAAHTLAGTSVQNI | 291 | Q5VYY2 | |
| VGILRTTHINTVSSY | 96 | Q96J86 | |
| LGLFSTIHDSIQYVQ | 321 | P51654 | |
| FTITKTVEYLHAQGV | 521 | P51812 | |
| FAAVNGNVIHVYTTT | 486 | Q96MR6 | |
| GNVIHVYTTTSLENI | 491 | Q96MR6 | |
| LQSETVHYKRGVSQQ | 156 | O60291 | |
| SGILIQFEQIVAVYH | 326 | Q16206 | |
| IHSTNEVTRIYNVIG | 346 | Q04609 | |
| ASTQYTAAVVVIHFL | 196 | P49286 | |
| TGVRSLSFYQHIITV | 351 | Q5VW00 | |
| SQQVIVQGVHELYDL | 326 | Q8IUF1 | |
| SQQVIVQGVHELYDL | 326 | Q9BRT8 | |
| THTNQAFEISLYGTV | 356 | P06858 | |
| LSLIATSYGHVLQAV | 211 | Q8NG97 | |
| QNGVQIYDRTSVLHV | 201 | Q8NCN5 | |
| VVYLHNNNISVVGSS | 296 | P07585 | |
| DTVQHGVEGLTYLLT | 56 | Q86X83 | |
| TDIVNIISNISYTAH | 341 | Q5KU26 | |
| HQYITEVQASGIELI | 836 | O60229 | |
| RLENITTGTYTIHAQ | 366 | Q15155 | |
| GHLYGTSVDAVQTVL | 501 | Q96JB8 | |
| SQYHTVAGNDIKISV | 526 | P42356 | |
| YTDAVNNTRVVGHSI | 131 | Q9Y5X9 | |
| ITEIHEQTYINGLLT | 276 | Q9UBG0 | |
| TLYQHNLTGILETAV | 591 | Q96CW5 | |
| IIADSVTSQVHNIYS | 1446 | P98164 | |
| VTSQVHNIYSLVENG | 1451 | P98164 | |
| LGLRVQYNTTIAHVT | 136 | Q8IWF2 | |
| ISVYSGSDRHAVQVI | 36 | Q8NDX5 | |
| HSSLIQVYEAFIQSG | 526 | Q8TE96 | |
| KSLNQHSGSYEVIVA | 4846 | Q9UPN3 | |
| SLSHLQNEYVVQGAI | 311 | Q96CB9 | |
| VEVVLQHVDTGNSYL | 141 | Q8IVV7 | |
| SHYVTLIIGDADNQV | 1026 | A2PYH4 | |
| LTVHGAQVLDSAIYS | 1776 | Q5VST9 | |
| QQEGTTYSLVLRHVA | 6406 | Q5VST9 | |
| ATYAVAVVGNITLLH | 36 | Q8NGF1 | |
| TSHDYLGQETLTEIQ | 576 | O60353 | |
| VDHTGEYGNLVTIQS | 2671 | Q13315 | |
| TVLSQVYSKVHNGSE | 4226 | P04114 | |
| ALNTIVTVYNVHGDQ | 1386 | Q14008 | |
| TDINVVVYHGSLISR | 931 | Q3L8U1 | |
| QLQVTATETHLNIYG | 316 | Q9BYE9 | |
| GIIHLSVINNQYEET | 3586 | Q4G0P3 | |
| NIIVTTVQYLSSALH | 1006 | Q8IZD9 | |
| HVITDIQVGSRINYS | 566 | P17927 | |
| HVITDIQVGSRINYS | 1016 | P17927 | |
| HITRQNSVGEIYSLQ | 271 | Q6PKX4 | |
| SVLVASGYRHNITSV | 71 | Q96T91 | |
| QQLTYATHVTEIISF | 276 | P51685 | |
| ESSQEYVTLQGISHV | 241 | Q5XKL5 | |
| AASVTGHTNIVEYLI | 221 | Q9BSK4 | |
| SQQVIVQGVHELYDL | 326 | Q5JTY5 | |
| TIGQSSAEYVLIVHD | 301 | Q8N3J6 | |
| SQGYNVNAVTLDHVT | 91 | Q8WWX0 | |
| YLQVSLSHITGENIV | 76 | Q96GE4 | |
| YHILTSHQTLTIQGE | 461 | Q9NS15 | |
| TVTGHQEQTYLQKET | 416 | Q71RC2 | |
| DIQHAGVQYILDSVI | 91 | O00754 | |
| TDSEVLTHYNITGNT | 91 | Q96DN0 | |
| GQAITLVTQYDIHLV | 346 | Q9Y6V7 | |
| QIENVHGYVLQSHIS | 51 | Q15700 | |
| LHYIATNGESAVVQL | 256 | Q9BY44 | |
| KVYHTNQTTFIIGET | 1216 | Q5T890 | |
| IVTNTSEGHLYVVSN | 131 | P48728 | |
| NVTQEDAGSYTLHII | 111 | Q00888 | |
| INTSDTVQHGAVYSL | 56 | Q6IQ49 | |
| EVIEHYLNELISQGT | 161 | O43304 | |
| IHTFQGSEEQTVVYV | 886 | Q8NG08 | |
| QLTTVNGSYHIVKAL | 411 | Q5VU65 | |
| TVLEAGTYHVQLRAT | 1686 | P98161 | |
| QLLDVIHYVNGVSTQ | 1926 | Q12923 | |
| IGVFNSTVHTAYALQ | 151 | Q8NGZ0 | |
| VYSHFNETLLGVSVI | 1151 | P33527 | |
| VSNAVSYRTQHTGVL | 116 | Q9H3N8 | |
| IVEHTLNQNGYTLVI | 491 | P08581 | |
| QIDQYVGLVTNQLSH | 501 | O75298 | |
| VTIQAYSSIIGLQSH | 151 | Q5T011 | |
| YSSIIGLQSHQVLVQ | 156 | Q5T011 | |
| LTSVTNHGYRVQVEN | 321 | Q9UPQ4 | |
| QLYVASAVGVTHLSL | 531 | Q13275 | |
| GNSLVIYVVLRHTAS | 61 | P32745 | |
| VTQEGQTLYAHLSKQ | 2466 | Q8NF91 | |
| GQSSLTVTNVTEEHY | 271 | Q13449 | |
| NVTQEDAGSYTLHII | 111 | Q9UQ74 | |
| SETVHLANGVYTSLQ | 2841 | Q96Q15 | |
| HIQLQLSAESVGEVY | 56 | P05230 | |
| GATIKRIQQQTHTYI | 346 | Q5U5Q3 | |
| TVSAQKNVEHGIIYI | 66 | Q8IYU8 | |
| TVAYLQAHALTTEGI | 266 | Q07960 | |
| VTHYILQTFLSLAVG | 356 | Q6P5W5 | |
| VSQNGQLIHYTESIS | 446 | Q9NY91 | |
| YLHSQVVSVGQEPVL | 541 | Q03519 | |
| FNADGIHQYTVSLVT | 1596 | Q9NT68 | |
| QLHVTYLVSGSLIQN | 56 | Q15054 | |
| IIYINSIGELEIHNT | 201 | O60811 | |
| NVTQEDTGSYTLHII | 111 | Q13046 | |
| IHIVNVESFTLSGYV | 166 | Q5T5C0 | |
| LDGVIQFYHTTIESV | 131 | Q96P63 | |
| AFILAVIVNSYHTGQ | 536 | Q8N122 | |
| EQRTTVQGQVYFLHT | 241 | Q9HCE7 | |
| RSGTLTYEAVHQTTQ | 201 | P53597 | |
| TYEAVHQTTQVGLGQ | 206 | P53597 | |
| TQVLLLVASETGHVY | 181 | P11831 | |
| VYNTVSEGTHFLETI | 191 | Q13433 | |
| QIYQGILTASRQSHV | 461 | Q8TE77 | |
| ITGSSQDTYVLHLVN | 131 | Q96SE0 | |
| NALVLYVGTQAIAHI | 2216 | A5YKK6 | |
| INHTIITSYSIENLQ | 1656 | Q96JI7 | |
| AVSVAVVNLQYQGAH | 311 | P50336 | |
| IHNTVFQVVLGYVEL | 281 | Q96JG6 | |
| TATQTGHTLLEDYQI | 616 | Q8N0X7 | |
| TEVIHTGTLQRQASY | 66 | A2RRD8 | |
| THLFVVTTENVQSYI | 201 | Q9H270 | |
| HTYISLILGTGEVNV | 361 | Q5VTQ0 | |
| DSLTYTVQHQVLGSD | 1316 | Q15772 | |
| HYVTSTDVQFIAVTG | 271 | O95210 | |
| ETYQVISQAAVVHAT | 66 | Q96DB5 | |
| QLQIHIETIEISGYS | 1026 | Q92545 | |
| IQTTNRYGQLTILHS | 401 | Q2MV58 | |
| NAVISHIDQTALAVY | 1081 | P29144 | |
| QAYRLISVVSHIGSS | 821 | Q9HBJ7 | |
| VDVVHLALYNLGVQS | 261 | Q5T6S3 | |
| GQSIHQVTVAQSYSL | 406 | O75886 | |
| INGTHQYTVSLVTGD | 1526 | Q9P273 | |
| IYHNITGISVDVHQQ | 321 | P08922 | |
| TGISVDVHQQIVYFS | 326 | P08922 | |
| TYVIQRQSVLTGHTD | 766 | P08922 | |
| FQTTESVHIYNVTLV | 3491 | Q86WI1 | |
| SLHYTGESQLTEVLQ | 971 | Q96AE7 | |
| INSLTGANITVYHTF | 141 | Q9H040 | |
| IVLNSIEQYQAHVSG | 246 | Q9UL40 | |
| TENYELVGVIVHSGQ | 1951 | Q9UPU5 | |
| NVTVQVAGETYSLHV | 151 | P35442 | |
| VEYEGNIHTSLAIAQ | 346 | Q9BXT5 | |
| LIVQDHYVFVQLTSG | 371 | Q8WY21 | |
| YTTTQQVVKLIGSHT | 3556 | Q5T4S7 | |
| GNTEVIHTGTLQRYQ | 11 | Q6ZNG1 | |
| VEQIVSALLGDHYVQ | 1341 | Q04912 | |
| GQVIQLEDGTTAYIH | 31 | P36508 | |
| LEDGTTAYIHQVTVQ | 36 | P36508 | |
| LVVTGSGEHASVYQI | 556 | Q9H808 | |
| VTLENYTHLVSIGLQ | 56 | Q99676 | |
| IIVVYVSQTSQEGAA | 546 | Q9Y6Q6 | |
| QSVSSAYTIAVVVFH | 181 | P48039 | |
| AVVHNYSAVVLGTTA | 236 | Q8N9F0 | |
| NSASNVYTVELHIGK | 111 | Q14324 | |
| IIHGQTSVIEQIVYV | 496 | Q00653 |